Rare Respiratory and Neurologic Adverse Reactions to Azacitidine in the Treatment of Myelodysplastic Syndrome of Patients Treated at the Ottawa Hospital

Azin Ahrari, Mitchell Sabloff, Chris Bredeson, Smita Pakhale, Carolina Souza, Jocelyn Zwicker, Dawn Sheppard

Abstract


Myelodysplastic syndromes (MDSs) are a heterogeneous group of disorders negatively affecting the bone marrow and resulting in multiple cytopenias. MDS ultimately progresses to acute myeloid leukemia (AML). Azacitidine was the first hypomethylating agent approved in Canada for patients with high risk MDS and patients with AML with 20-30% blasts. Azacitidine has a relatively low toxicity profile and is well tolerated by most age groups. We conducted a retrospective chart review of patients who received azacitidine at our institution, over a 3.5-year period. To our knowledge, this report presents the first case of peripheral neuropathy and an additional case of pneumonitis as rare adverse effects of azacitidine.




J Hematol. 2015;4(4):231-234
doi: http://dx.doi.org/10.14740/jh227w


Keywords


Myelodysplastic syndromes; Hypomethylating agents; Pneumonitis; Peripheral neuropathy; Azacitidine

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!